First day of trading in Sensidose AB
Today is the first day of trading in Sensidose AB, a Swedish pharmaceutical company which develops and sells individualised dosing of medicines for the medical treatment of Parkinson’s disease.Sensidose has developed the drug Flexilev® which, in combination with the proprietary MyFID® dosing device, individualises and adjust the treatment of Parkinson's disease. The Company's vision is to improve the quality of life for patients with chronic diseases through improved individualised medication, leading to better efficacy and reduced side effects of given treatment. The Company is now in a